Mont Sorcier Project, Quebec, Canada Image of Mont Sorcier in Quebec, Canada Feasibility Study completion targeted for Q2 2026Targeting Increased Production rate of 8 MM tpa of 67% iron concentrate in a 2-stage phased development approach TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- CERRADO GOLD ("Cerrado" or the "Company”) is pleased to provide an update on the progress and anticipated changes to the development proposal for its Mont Sorcier high purity magnetite iron project located on the traditional ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Certara (NasdaqGS:CERT) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker2Good day, and thank you for standing by. Welcome to the Certara Q3 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you need to press Star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press Star 11 again. Please be advised ...

Third Quarter 2025 Financial Results November 6, 2025 Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the "Company," "Certara," "we," "us," and "our" refer to Certara, Inc. and its consolidated subsidiaries. Trademarks and Service Marks The Certara design logo, "Certara," and ou ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39799 Certara, Inc. (Exact name of registrant as specified in its charter) (St ...

Exhibit 99.1 Certara Reports Third Quarter 2025 Financial Results Updates Full Year 2025 Financial Guidance RADNOR, PA— November 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: "In the third quarter, we continued to make good progress towards our full-year revenue and profitability targets," said William Feehery, Chief Executive Officer. "We recently launched ...

Updates Full Year 2025 Financial GuidanceRADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Servi ...

New cloud capabilities cut time to create Tables, Figures, and Listings by 50%RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific ...

产品发布核心 - 公司宣布推出Certara IQ，一个可扩展的、由人工智能驱动的定量系统药理学解决方案 [1] 行业背景与重要性 - QSP已成为现代药物发现和开发的基石，自2013年以来基于QSP的美国FDA申报数量大约每1.4年翻一番 [2] - QSP结合计算模型和实验数据来检查药物如何与生物系统和疾病过程相互作用，使科学家能够预测关键结果，如最佳剂量、治疗窗口和理想患者群体 [2] - 这些能力对于新颖或复杂的治疗模式尤其关键 [2] 产品功能与优势 - Certara IQ消除了历史上限制QSP采用的许多计算和工作流程挑战，包括模型复用性差、模拟时间长、编码环境复杂以及缺乏标准化 [3] - 其人工智能驱动软件减少了手动工作并增强了可重复性，使QSP建模更快、更简单、更具影响力 [3] - 通过直观的、生成式AI支持的界面增强模型的可重复性和可重用性，用于构建和可视化QSP模型 [5] - 通过包含科学验证的预建QSP模型、工作流程和报告模板的深度知识库加速模型创建 [5] - 通过高性能模拟引擎减少计算瓶颈，其运行模拟速度比传统工具快数千倍 [5] - 通过用于“假设”分析的无代码界面赋能决策制定，以快速评估可行性、识别数据差距并优化剂量和药物特性 [5] 战略定位与影响 - Certara IQ代表着使生物模拟成为整个药物发现和开发价值链基础能力的关键一步 [3] - 通过大规模结合人工智能、系统建模和科学专业知识，使公司能够做出更明智的研发管线决策、降低开发风险并加速新疗法向患者的交付 [3] 公司概况 - 公司是一家利用专有生物模拟软件、技术和服务来加速药物研发、转变传统药物发现和开发的全球领导者 [4] - 其客户包括超过2,400家生物制药公司、学术机构和遍布70个国家的监管机构 [4]